Tags

Type your tag names separated by a space and hit enter

Successful migraine prophylaxis with naproxen sodium.

Abstract

Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.

Links

  • Aggregator Full Text
  • Authors

    , ,

    Source

    Neurology 35:9 1985 Sep pg 1304-10

    MeSH

    Adult
    Female
    Humans
    Male
    Middle Aged
    Migraine Disorders
    Naproxen

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    4022376

    Citation

    Welch, K M., et al. "Successful Migraine Prophylaxis With Naproxen Sodium." Neurology, vol. 35, no. 9, 1985, pp. 1304-10.
    Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35(9):1304-10.
    Welch, K. M., Ellis, D. J., & Keenan, P. A. (1985). Successful migraine prophylaxis with naproxen sodium. Neurology, 35(9), pp. 1304-10.
    Welch KM, Ellis DJ, Keenan PA. Successful Migraine Prophylaxis With Naproxen Sodium. Neurology. 1985;35(9):1304-10. PubMed PMID: 4022376.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Successful migraine prophylaxis with naproxen sodium. AU - Welch,K M, AU - Ellis,D J, AU - Keenan,P A, PY - 1985/9/1/pubmed PY - 1985/9/1/medline PY - 1985/9/1/entrez SP - 1304 EP - 10 JF - Neurology JO - Neurology VL - 35 IS - 9 N2 - Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/4022376/full_citation L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=4022376.ui DB - PRIME DP - Unbound Medicine ER -